Story preview
Continue reading on the publisher site for the full article.
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
13
in the last 3 days
First reported
9 days ago
12 outlets since
Countries
12 other outlets reported this story in the last 3 days.
Moderna Inc. stocks have been trading up by 4.13 percent after promising mRNA pipeline progress boosted investor optimism. Key Takeaways NIH-backed cancer vaccine initiative sparked a roughly 9%–13% surge in MRNA as traders priced in a bigger oncology opportunity. Index provider Nasdaq is adding
Moderna shares declined as investors engaged in profit-taking following recent gains.Wall Street analysts highlighted valuation friction due to unprofitability and high cash burn.The company reported an annual revenue of $1.94B and a net loss.
Moderna Inc. stocks have been trading up by 4.22 percent after upbeat mRNA pipeline data strengthened investor confidence. Key Takeaways Shares ripped 9%–12.5% after news that the US NIH will help drive a new cancer‑vaccine partnership, refocusing the MRNA story on oncology rather than only COVID. Index managers will…